Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer

Stopped early · Not applicable

Conditions studied: Breast Cancer

In brief

The purpose of this study is: 1. To evaluate the hypothesis: Can PEM Flex Solo II PET scanner ascertain response to neoadjuvant chemotherapy in patients with breast cancer? 2. To compare the results from the PEM Flex Solo II PET scanner to the standard of care bilateral breast MRI.

Key facts

Study ID

NCT01012440

Run by

University of Chicago

People needed

5

Starts

2009-11-01

Expected to finish

2012-05-01

Last updated by the study team

2015-07-27

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women 18-75 years old with newly diagnosed breast cancer who are considered candidates for breast conserving surgery (i.e., lumpectomy)

You may not qualify if…

• Children (< 18 years old)
• Pregnant or Lactating women
• Diabetic patients (Type I or II)
• Patients who are scheduled for a sentinel node procedure using radioactive Tc-99m within 24 hours of PEM
• Patients who have NOT undergone a standard of care bilateral breast MRI

Where it is running

• The University of Chicago Medical Center — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.